DOSEF (Doseology Sciences) EBIT: $-0.87 Mil (TTM As of Mar. 2026)

What is Doseology Sciences EBIT?

Doseology Sciences DOSEF -16.16% 33 EBIT is $-0.87 Mil as of Mar. 2026. GuruFocus rates DOSEF with a GF Score™ of 33/100 and a GF Value™ of $0.29 (Possible Value Trap). The stock has 4 warning signs investors should review.

Doseology Sciences's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-0.31 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.87 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Doseology Sciences's annualized ROC % for the quarter that ended in Mar. 2026 was -241.49%. Doseology Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -583.37%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Doseology Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -675.78%.

Doseology Sciences (OTCPK:DOSEF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Doseology Sciences's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-1.228 * ( 1 - 0% )	/	( (0.482	+	0.535)	/ 2 )
=	-1.228	/	0.5085
=	-241.49 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.013	-	0.051	-	( 0.48	-	max(0, 0.051	-	0.762	+	0.48	))
=	0.482

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.861	-	0.059	-	( 0.267	-	max(0, 0.059	-	0.608	+	0.267	))
=	0.535

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Doseology Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.228	/	( ( (0 + max(0.189, 0))	+	(0 + max(0.232, 0)) )	/	2 )
=	-1.228	/	( ( 0.189	+	0.232 )	/	2 )
=	-1.228	/	0.2105
=	-583.37 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.009	+	0.06	+	0.171)	-	(0.051	+	0	+	0)
=	0.189

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.022	+	0.109	+	0.16)	-	(0.059	+	0	+	0)
=	0.232

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Doseology Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-0.865	/	0.128
	=	-675.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Doseology Sciences EBIT Related Terms

Doseology Sciences EBIT Historical Data

* Premium members only.

The historical data trend for Doseology Sciences's EBIT can be seen below:

Doseology Sciences EBIT Chart

Doseology Sciences Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

EBIT

Get a 7-Day Free Trial

-1.28

-1.46

-1.31

-0.28

-0.35

Doseology Sciences Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															-0.06	-0.18	-0.13	-0.25	-0.31

DOSEF vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Doseology Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Doseology Sciences EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Doseology Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Doseology Sciences's EV-to-EBIT falls into.

Save Embed

33GF Score

Doseology Sciences Inc DOSEF

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Doseology Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.87 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-0.87 Mil mean?

Doseology Sciences (DOSEF) has a EBIT of $-0.87 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Doseology Sciences.

Is Doseology Sciences' EBIT too high?

Doseology Sciences' current EBIT is $-0.87 Mil. Overall, Doseology Sciences has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Doseology Sciences' EBIT compare to VRTX and REGN?

Doseology Sciences' EBIT of $-0.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Doseology Sciences. Doseology Sciences's current EBIT is $-0.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Doseology Sciences stock overvalued right now?

Based on GuruFocus' analysis, Doseology Sciences (DOSEF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.29, compared to a current price of $0.11 — trading 61.3% below its estimated fair value. The current EBIT is $-0.87 Mil. Doseology Sciences' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Doseology Sciences (DOSEF), the current EBIT is $-0.87 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Doseology Sciences (DOSEF) Overvalued in 2026?

Based on GuruFocus' analysis, Doseology Sciences stock appears to be undervalued. The current stock price of $0.11 is trading 61.3% below its estimated GF Value™ of $0.29. GuruFocus considers Doseology Sciences to be Possible Value Trap.

Key valuation signals for DOSEF:

EBIT: $-0.87 Mil
GF Value™: $0.29 vs. price of $0.11 (61.3% below fair value)
GF Score™: 33/100 with 4 warning signs

No single metric tells the full story. See the DOSEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Doseology Sciences Business Description

Industry Healthcare Biotechnology

Comparable Companies TSXV:RKV XCNQ:MBIO XCNQ:BIOV XCNQ:NURL XCNQ:GREY TSX:APLI TSXV:QPT XCNQ:ASEP TSXV:XRTX XCNQ:HEAL VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges MOOD:Canada

Address 9-3151 Lakeshore Road, Suite 305, Kelowna, BC, CAN, V1W 3S9

Website https://www.doseology.com

Doseology Sciences Inc is a diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on the psychedelic and non-psychedelic compounds, also sale of its branded functional mushroom products. It offers cutting-edge therapeutic products and services, with the focus of making a meaningful impact on the mental health pandemic and improving overall health. Geographically earns it revenue from Canada.

33GF Score

Get the complete analysis for DOSEF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11

Price

$0.29

GF Value

View DOSEF Analysis

See EBIT data for all stocks →